Cardiac sympathetic neuronal imaging using PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 1 SUPPL., 2007, Pages

  Lautamäki, Riikka ^a   Tipre, Dnyanesh ^a   Bengel, Frank M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Nuclear Medicine Department   (United States)

Author keywords

Cardiac autonomic nervous system; Catecholamines; PET; Sympathetic nervous system

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE C 11; 3 HYDROXYEPHEDRINE C 11; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE C 11; 6 FLUORODOPA F 18; 6 FLUOROMETARAMINOL F 18; CATECHOLAMINE RECEPTOR; CGP 12388 C 11; FLUORODOPAMINE F 18; GB 67 C 11; HYDROXYEPHEDRINE C 11; PHENYLEPHRINE C 11; PHOSGENE C 11; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

CHEMICAL STRUCTURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC IMAGING; HEART DISEASE; HEART TRANSPLANTATION; HUMAN; ISCHEMIC HEART DISEASE; NEUROIMAGING; NEUROPHYSIOLOGY; NON INVASIVE PROCEDURE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; REVIEW;

AUTONOMIC NERVOUS SYSTEM DISEASES; HEART; HEART DISEASES; HUMANS; NEURONS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 34250727095     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0442-1     Document Type: Review

References (85)

1. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 2001;33(5):887-905.
2. Elsinga PH, van Waarde A, Vaalburg W. Receptor imaging in the thorax with PET. Eur J Pharmacol 2004;499(1-2):1-13.
3. Francis GS. Modulation of peripheral sympathetic nerve transmission. J Am Coll Cardiol 1988;12(1):250-4.
4. Tobes MC, Jaques S Jr, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 1985;26(8):897-907.
5. Melon PG, Nguyen N, DeGrado TR, et al. Imaging of cardiac neuronal function after cocaine exposure using carbon-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol 1994;23(7):1693-9.
6. Russ H, Gliese M, Sonna J, Schomig E. The extraneuronal transport mechanism for noradrenaline (uptake2) avidly transports 1-methyl-4- phenylpyridinium (MPP+). Naunyn Schmiedebergs Arch Pharmacol 1992;346(2):158-65.
7. Salt PJ. Inhibition of noradrenaline uptake 2 in the isolated rat heart by steroids, clonidine and methoxylated phenylethylamines. Eur J Pharmacol 1972;20(3):329-40.
8. Langer O, Halldin C. PET and SPET tracers for mapping the cardiac nervous system. Eur J Nucl Med Mol Imaging 2002;29(3):416-34.
9. Schwaiger M, Kalff V, Rosenspire K, et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 1990;82(2):457-64.
10. DeGrado TR, Hutchins GD, Toorongian SA, Wieland DM, Schwaiger M. Myocardial kinetics of carbon-11-meta-hydroxyephedrine: retention mechanisms and effects of norepinephrine. J Nucl Med 1993;34(8):1287-93.
11. Schwaiger M, Hutchins GD, Kalff V, et al. Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography. J Clin Invest 1991;87(5):1681-90.
12. 11C-meta-hydroxyephedrine retention on norepinephrine transporter density. J Nucl Med 2006;47(9):1490-6.
13. Nguyen NT, DeGrado TR, Chakraborty P, Wieland DM, Schwaiger M. Myocardial kinetics of carbon-11-epinephrine in the isolated working rat heart. J Nucl Med 1997;38(5):780-5.
14. 11C]hydroxyephedrine and positron emission tomography. Circulation 2000;101(5):516-23.
15. 11C]phenylephrine kinetics: studies in isolated rat heart. J Nucl Med 1999;40(2):323-30.
16. Raffel DM, Corbett JR, del Rosario RB, et al. Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons. J Nucl Med 1996;37(12):1923-31.
17. 11C]phenylephrine kinetics to monoamine oxidase activity in normal human heart. J Nucl Med 1999;40(2):232-8.
18. Tipre DN, Goldstein DS. Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med 2005;46(11):1775-81.
19. Goldstein DS, Robertson D, Esler M, Straus SE, Eisenhofer G. Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med 2002;137(9):753-63.
20. Goldstein DS, Holmes C, Cannon RO, III, Eisenhofer G, Kopin IJ. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 1997;336(10):696- 702.
21. 18F] fluorodopamine: initial findings in humans. J Am Coll Cardiol 1993;22(7):1961-71.
22. Goldstein DS, Chang PC, Eisenhofer G, et al. Positron emission tomographic imaging of cardiac sympathetic innervation and function. Circulation 1990;81(5):1606-21.
23. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol 2004;11(5):603-16.
24. Law MP. Demonstration of the suitability of CGP 12177 for in vivo studies of beta-adrenoceptors. Br J Pharmacol 1993;109(4):1101-9.
25. Delforge J, Mesangeau D, Dolle F, et al. In vivo quantification and parametric images of the cardiac beta-adrenergic receptor density. J Nucl Med 2002;43(2):215-26.
26. van Waarde A, Elsinga PH, Doze P, et al. A novel beta-adrenoceptor ligand for positron emission tomography: evaluation in experimental animals. Eur J Pharmacol 1998;343(2-3):289-96.
27. 18F]fluoro-CGP 12388) for visualization of beta-adrenoceptors with positron emission tomography. J Med Chem 1997;40(23):3829-35.
28. 11C]CGP12388 and positron emission tomography. Eur J Pharmacol 2001;433(2-3):173-6.
29. 11C-CGP12388. J Nucl Med 2004;45(3):471-7.
30. 11C]CGP 12388 and a tracer kinetic model. Eur J Nucl Med Mol Imaging 2002;29(3):295-304.
31. 11C]GB67, a novel radioligand for imaging myocardial alpha 1-adrenoceptors with positron emission tomography. Eur J Nucl Med 2000;27(1):7-17.
32. 18F]fluoroethoxybenzovesamicol as a new PET tracer of cholinergic neurons of the heart. Nucl Med Biol 1994;21(2):189-95.
33. Syrota A, Comar D, Paillotin G, et al. Muscarinic cholinergic receptor in the human heart evidenced under physiological conditions by positron emission tomography. Proc Natl Acad Sci USA 1985; 82(2):584-8.
34. 18F]fluoro-D-glucose- A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo. Clin Res Cardiol 2006;95(2):105-9.
35. Kao AC, Van TP, III, Shaeffer-McCall GS, et al. Central and peripheral limitations to upright exercise in untrained cardiac transplant recipients. Circulation 1994;89(6):2605-15.
36. Kao AC, Van TP, III, Shaeffer-McCall GS, et al. Allograft diastolic dysfunction and chronotropic incompetence limit cardiac output response to exercise two to six years after heart transplantation. J Heart Lung Transplant 1995;14(1 Pt 1):11-22.
37. Di Carli MF, Tobes MC, Mangner T, et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med 1997;336(17):1208-15.
38. Wilson RF, Christensen BV, Olivari MT, et al. Evidence for structural sympathetic reinnervation after orthotopic cardiac transplantation in humans. Circulation 1991;83(4):1210-20.
39. Bengel FM, Ueberfuhr P, Ziegler SI, et al. Serial assessment of sympathetic reinnervation after orthotopic heart transplantation. A longitudinal study using PET and C-11 hydroxyephedrine. Circulation 1999;99(14):1866-71.
40. Bengel FM, Ueberfuhr P, Hesse T, et al. Clinical determinants of ventricular sympathetic reinnervation after orthotopic heart transplantation. Circulation 2002;106(7):831-5.
41. Bengel FM, Ueberfuhr P, Schiepel N, et al. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med 2001;345(10):731-8.
42. Bengel FM, Ueberfuhr P, Karja J, et al. Sympathetic reinnervation, exercise performance and effects of beta-adrenergic blockade in cardiac transplant recipients. Eur Heart J 2004;25(19):1726-33.
43. Bengel FM, Ueberfuhr P, Ziegler SI, et al. Non-invasive assessment of the effect of cardiac sympathetic innervation on metabolism of the human heart. Eur J Nucl Med 2000;27(11):1650-7.
44. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26(5):1553-79.
45. Allman KC, Stevens MJ, Wieland DM, et al. Noninvasive assessment of cardiac diabetic neuropathy by carbon-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol 1993;22(5):1425-32.
46. Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 1998;98(10):961-8.
47. Schmid H, Forman LA, Cao X, Sherman PS, Stevens MJ. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes. Diabetes 1999;48(3):603-8.
48. Rimoldi OE, Drake-Holland AJ, Noble MI, Camici PG. Basal and hyperaemic myocardial blood flow in regionally denervated canine hearts: an in vivo study with positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34(2):197-205.
49. Stevens MJ, Dayanikli F, Raffel DM, et al. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy. J Am Coll Cardiol 1998;31(7):1575-84.
50. Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 1999;100(8):813-9.
51. Pop-Busui R, Kirkwood I, Schmid H, et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 2004;44(12):2368-74.
52. Stevens MJ, Raffel DM, Allman KC, Schwaiger M, Wieland DM. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism 1999;48(1):92-101.
53. Bengel FM, Ueberfuhr P, Schafer D, et al. Effect of diabetes mellitus on sympathetic neuronal regeneration studied in the model of transplant reinnervation. J Nucl Med 2006;47(9):1413-9.
54. Chen PS, Chen LS, Cao JM, et al. Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. Cardiovasc Res 2001;50(2):409-16.
55. Spyrou N, Rosen SD, Fath-Ordoubadi F, et al. Myocardial beta-adrenoceptor density one month after acute myocardial infarction predicts left ventricular volumes at six months. J Am Coll Cardiol 2002;40(7):1216-24.
56. Schwaiger M, Guibourg H, Rosenspire K, et al. Effect of regional myocardial ischemia on sympathetic nervous system as assessed by fluorine-18-metaraminol. J Nucl Med 1990;31(8):1352-7.
57. 11C- hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med 2005;46(8):1368-74.
58. Bulow HP, Stahl F, Lauer B, et al. Alterations of myocardial presynaptic sympathetic innervation in patients with multi-vessel coronary artery disease but without history of myocardial infarction. Nucl Med Commun 2003;24(3):233-9.
59. Allman KC, Wieland DM, Muzik O, et al. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol 1993;22(2):368-75.
60. Fallen EL, Coates G, Nahmias C, et al. Recovery rates of regional sympathetic reinnervation and myocardial blood flow after acute myocardial infarction. Am Heart J 1999; 137(5):863-9.
61. Fricke E, Fricke H, Eckert S, et al. Myocardial sympathetic innervation in patients with chronic coronary artery disease: is reduction in coronary flow reserve correlated with sympathetic denervation? Eur J Nucl Med Mol Imaging 2007;34(2):206-11.
62. 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation 1993;87(4):1169-78.
63. Choudhury L, Rosen SD, Lefroy DC, et al. Myocardial beta adrenoceptor density in primary and secondary left ventricular hypertrophy. Eur Heart J 1996;17(11):1703-9.
64. Schafers M, Dutka D, Rhodes CG, et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 1998;82(1):57-62.
65. 11C]CGP12388. Eur J Nucl Med Mol Imaging 2005;32(4):443-7.
66. 11C]hydroxyephedrine, a specific tracer for sympathetic nerve endings, and its functional correlates in congestive heart failure. Am J Cardiol 1999;84(5):568-74.
67. Hartmann F, Ziegler S, Nekolla S, et al. Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography. Heart 1999;81(3):262-70.
68. Ungerer M, Hartmann F, Karoglan M, et al. Regional in vivo and in vitro characterization of autonomic innervation in cardiomyopathic human heart. Circulation 1998;97(2):174-80.
69. Pietila M, Malminiemi K, Ukkonen H, et al. Reduced myocardial carbon-11 hydroxyephedrine retention is associated with poor prognosis in chronic heart failure. Eur J Nucl Med 2001;28(3):373-6.
70. 11C- hydroxyephedrine PET, autonomic nervous control, and ventricular repolarization. J Nucl Med 2002;43(6):773-9.
71. Bengel FM, Permanetter B, Ungerer M, Nekolla SG, Schwaiger M. Relationship between altered sympathetic innervation, oxidative metabolism and contractile function in the cardiomyopathic human heart; a non-invasive study using positron emission tomography. Eur Heart J 2001;22(17):1594-600.
72. Bengel FM, Permanetter B, Ungerer M, Nekolla SG, Schwaiger M. Alterations of the sympathetic nervous system and metabolic performance of the cardiomyopathic heart. Eur J Nucl Med Mol Imaging 2002;29(2):198-202.
73. Matsuo K, Kurita T, Inagaki M, et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 1999;20(6):465-70.
74. Kies P, Wichter T, Schafers M, et al. Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation 2004;110(19):3017-22.
75. Wichter T, Schafers M, Rhodes CG, et al. Abnormalities of cardiac sympathetic innervation in arrhythmogenic right ventricular cardiomyopathy: quantitative assessment of presynaptic norepinephrine reuptake and postsynaptic beta-adrenergic receptor density with positron emission tomography. Circulation 2000;101(13):1552-8.
76. Schafers M, Lerch H, Wichter T, et al. Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia. J Am Coll Cardiol 1998;32(1):181-6.
77. 11C]HED in genotyped long QT patients: a potential amplifier role for severity of the disease. Am J Physiol Heart Circ Physiol 2003;285(3):H1286-93.
78. Calkins H, Lehmann MH, Allman K, Wieland D, Schwaiger M. Scintigraphic pattern of regional cardiac sympathetic innervation in patients with familial long QT syndrome using positron emission tomography. Circulation 1993;87(5):1616-21.
79. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56(1):33-9.
80. Goldstein DS. Cardiovascular aspects of Parkinson disease. J Neural Transm Suppl 2006;(70):339-42.
81. Goldstein DS. Cardiac sympathetic neuroimaging to distinguish multiple system atrophy from Parkinson disease. Clin Auton Res 2001;11(6):341-2.
82. 11C]meta- Hydroxyephedrine positron emission tomography in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2003;30(1):127-31.
83. Goldstein DS, Holmes C, Li ST, et al. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 2000;133(5):338-47.
84. Sharabi Y, Eldadah B, Li ST, et al. Neuropharmacologic distinction of neurogenic orthostatic hypotension syndromes. Clin Neuropharmacol 2006;29(3):97-105.
85. Raffel DM, Koeppe RA, Little R, et al. PET measurement of cardiac and nigrostriatal denervation in parkinsonian syndromes. J Nucl Med 2006; 47(11):1769-77.